Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aclaris Therapeutics

1.44
-0.0100-0.69%
Post-market: 1.460.0191+1.33%16:20 EDT
Volume:401.67K
Turnover:585.57K
Market Cap:155.92M
PE:-1.00
High:1.49
Open:1.46
Low:1.44
Close:1.45
Loading ...

Aclaris Therapeutics Highlights Clinical Pipeline and Outlook

TIPRANKS
·
30 Jun

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Jun

Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating

TIPRANKS
·
25 Jun

BRIEF-Aclaris Therapeutics Initiates Phase 1A/1B Program For Its Novel Bispecific Antibody Ati-052

Reuters
·
23 Jun

Aclaris Therapeutics Inc - Phase 1a Results Expected Early 2026, Phase 1B Results in H2 2026

THOMSON REUTERS
·
23 Jun

Aclaris Therapeutics Initiates Phase 1a/1B Program for Its Novel Bispecific Antibody ATI-052

THOMSON REUTERS
·
23 Jun

Wedbush Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)

TIPRANKS
·
09 Jun

Aclaris Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
06 Jun

BRIEF-Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug In Atopic Dermatitis

Reuters
·
02 Jun

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

THOMSON REUTERS
·
02 Jun

Aclaris Therapeutics Inc - Top Line Results Expected in Second Half of 2026

THOMSON REUTERS
·
02 Jun

Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments

TIPRANKS
·
30 May

Aclaris Therapeutics Initiated at Outperform by Wedbush

Dow Jones
·
28 May

Wedbush Initiates Aclaris Therapeutics at Outperform With $8 Price Target

MT Newswires Live
·
28 May

Aclaris Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $8

THOMSON REUTERS
·
28 May

Aclaris Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
15 May

Aclaris Therapeutics Reports Q1 2025 Financial Results

TIPRANKS
·
10 May

Aclaris Therapeutics Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
10 May

Aclaris Therapeutics price target lowered to $9 from $15 at Scotiabank

TIPRANKS
·
09 May

Aclaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May